💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇻🇳 Tiếng Việt

Sulesomab

CHEMBL2108809 Phase 4 Đã phê duyệt Antibody
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Sulesomab is a murine-derived anti-NCA-90 (normal cross-reactive antigen) Fab' fragment radiolabeled with technetium-99m, used as a radioimmunoscintigraphic agent for the diagnosis of appendicitis and peripheral osteomyelitis by targeting granulocyte surface antigens at sites of infection and inflammation. The antibody fragment binds to the NCA-90 antigen expressed on peripheral blood granulocytes and at sites of infection, allowing scintigraphic visualization of inflammatory foci. Fab' format reduces immunogenicity and allows rapid clearance compared to intact antibodies.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

Sulesomab is a murine-derived anti-NCA-90 (normal cross-reactive antigen) Fab' fragment radiolabeled with technetium-99m, used as a radioimmunoscintigraphic agent for the diagnosis of appendicitis and peripheral osteomyelitis by targeting granulocyte surface antigens at sites of infection and inflammation. The antibody fragment binds to the NCA-90 antigen expressed on peripheral blood granulocytes and at sites of infection, allowing scintigraphic visualization of inflammatory foci. Fab' format reduces immunogenicity and allows rapid clearance compared to intact antibodies.

Yes, Sulesomab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108809. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.